MRD testing is especially important in certain blood cancers, including acute lymphoblastic leukemia, acute myeloid leukemia, and multiple myeloma. Researchers are also studying its role in selected solid tumors, where testing methods and clinical applications vary.

The main purpose of MRD testing is to provide more detailed information about treatment response and disease status. It can help clinicians assess whether a treatment has reduced cancer cells below a particular detection threshold and whether additional monitoring may be appropriate.

How MRD Testing Works

MRD testing begins with collecting a suitable biological sample. Depending on the disease and the test, this may involve a blood sample, a bone marrow sample, or tumor-related material.

The laboratory then uses a specialized analytical method to identify cancer-associated cells, genetic changes, or molecular markers.

The results are interpreted alongside other clinical information, such as the cancer type, treatment history, symptoms, and standard laboratory findings. A negative MRD result does not necessarily mean that every cancer cell has disappeared. It means that the test did not detect disease above its established detection limit in the sample examined.

Importance of MRD Testing in Modern Diagnostics

MRD testing has become an important part of precision oncology because it can reveal changes that conventional diagnostic methods may not identify. Its usefulness depends on the cancer type, the treatment being evaluated, and the availability of a validated testing method.

Understanding Treatment Response

After cancer treatment, clinicians need reliable information about how well the disease has responded. MRD testing can provide a more sensitive assessment than some conventional methods.

For example, a patient with leukemia may have no obvious signs of disease under a routine examination, while a sensitive molecular test may still identify a small population of cancer-associated cells.

This additional information can help clinicians evaluate treatment response and determine appropriate follow-up plans.

Supporting Risk Assessment

In certain blood cancers, MRD status is associated with the likelihood of relapse. Patients with detectable MRD may have a different risk profile from patients whose results are negative, although the meaning varies by disease and treatment.

MRD results are therefore considered alongside other factors rather than used as a universal prediction of an individual's outcome.

Improving Disease Monitoring

Repeated MRD testing can help track changes in measurable disease over time. A result that changes from positive to negative may indicate a strong response, while a newly detectable or increasing signal may require further clinical assessment.

However, a single result should not be interpreted in isolation. Sample quality, testing sensitivity, biological variation, and the timing of collection can affect interpretation.

Who Uses MRD Testing?

MRD testing may be relevant to:

• Hematologists and oncologists monitoring selected blood cancers.

• Pathologists and laboratory scientists analyzing cancer-related samples.

• Clinical researchers studying treatment response and relapse.

• Patients and caregivers seeking a clearer understanding of disease monitoring.

• Healthcare teams evaluating whether evidence supports treatment adjustments.

MRD testing is not equally appropriate for every cancer or every stage of treatment. Its use should follow disease-specific clinical guidance.

Major MRD Testing Technologies

Different technologies identify residual disease in different ways. The most appropriate method depends on the cancer's biological characteristics, the sample available, the required sensitivity, and the clinical purpose.

Flow Cytometry

Flow cytometry examines individual cells as they pass through a laser-based detection system. It measures characteristics such as cell size, internal complexity, and the presence of specific surface or intracellular markers.

In leukemia and some other blood cancers, abnormal cells may display marker patterns that distinguish them from normal cells.

Key characteristics:

• Can analyze large numbers of cells relatively quickly.

• Identifies abnormal cell populations using marker combinations.

• Requires careful laboratory preparation and interpretation.

• May be affected by changes in cell markers during treatment.

Multiparameter flow cytometry is particularly useful when a laboratory needs to distinguish abnormal cells from normal or regenerating cells.

Polymerase Chain Reaction (PCR)

Polymerase chain reaction amplifies selected genetic sequences so that very small quantities of target DNA or RNA can be detected.

Quantitative PCR and digital PCR are related approaches with different measurement principles. Their suitability depends on whether a reliable disease-specific genetic target is available.

PCR-based MRD testing can be highly sensitive when the target is well established. However, some methods require an identifiable molecular marker, and not every patient has a suitable target for every assay.

Next-Generation Sequencing (NGS)

Next-generation sequencing examines genetic material across many targeted sequences in a single analytical process. In MRD testing, certain sequencing approaches can identify and quantify cancer-associated genetic sequences or rearrangements.

NGS may be useful when several molecular markers need to be examined or when highly sensitive tracking of a known cancer-associated sequence is possible.

Important considerations include sequencing depth, background errors, sample quality, bioinformatics methods, and the laboratory's validated detection threshold.

Comparing Major MRD Technologies

No single technology is best for every patient. The choice should reflect the disease, clinical question, validated laboratory method, and available evidence.

Recent Updates in MRD Testing Technologies

MRD testing continues to develop through improvements in molecular analysis, sequencing accuracy, and clinical research. Recent work focuses on detecting smaller quantities of disease while improving the reliability of laboratory interpretation.

Developments During 2025 and 2026

In March 2026, an updated European LeukemiaNet and DAVID working-party consensus document on MRD in acute myeloid leukemia described refinements in molecular testing recommendations. It discussed quantitative PCR, digital PCR, and ultra-high-sensitivity next-generation sequencing, along with the importance of validated methods and consistent sample preparation.

In January 2026, the United States Food and Drug Administration (FDA) issued draft guidance on using MRD negativity and complete response as endpoints in multiple myeloma clinical trials. The document addresses assay selection, trial design, and statistical considerations. It is draft guidance rather than a binding regulation.

Another important trend is the growing use of circulating tumor DNA (ctDNA) analysis for selected solid tumors. This approach looks for tumor-related DNA fragments in blood. Its usefulness varies by cancer type, and evidence that detecting a signal improves patient outcomes is still developing in many settings.

Emerging Laboratory Trends

Current areas of development include:

• More sensitive sequencing: Improved methods aim to detect very small quantities of cancer-associated genetic material.

• Digital PCR: Partition-based analysis can help quantify low levels of specific genetic targets.

• Personalized molecular tracking: Some approaches use genetic information from an individual's tumor to identify relevant DNA signals.

• Improved data analysis: Bioinformatics tools help laboratories distinguish genuine disease signals from background noise.

• Longitudinal monitoring: Researchers are evaluating how repeated testing can help explain changes in disease status over time.

These developments are promising, but a more sensitive test is not automatically more useful in every clinical situation. Evidence, assay validation, and the effect of results on medical decisions remain essential.

Laws, Policies, and Laboratory Standards

MRD testing is affected by medical-device regulations, laboratory quality requirements, privacy protections, and disease-specific clinical guidelines. The exact rules depend on the country and the type of test being performed.

United States Regulatory Considerations

The FDA regulates relevant diagnostic tests according to their intended use and applicable regulatory pathway. Laboratories and test developers must consider analytical performance, clinical evidence, quality controls, and appropriate reporting.

The FDA's January 2026 draft guidance on MRD endpoints in multiple myeloma provides recommendations for clinical-trial development. It should not be interpreted as approval of every MRD assay or as a requirement to use MRD testing for every patient.

Laboratory Quality and Patient Privacy

Laboratories should follow applicable requirements for:

• Validating analytical methods before clinical use.

• Maintaining appropriate sample handling and documentation.

• Using quality-control procedures to monitor test performance.

• Reporting detection limits and relevant limitations.

• Protecting patient information and genetic data.

• Following informed-consent and data-protection requirements where applicable.

Considerations in India and Other Countries

In India, diagnostic laboratories must consider applicable medical-device requirements, laboratory regulations, clinical establishment rules where relevant, and data-protection obligations. The requirements depend on the test, laboratory setting, and current national and state rules.

Clinical guidelines from recognized hematology and oncology organizations can help clinicians understand when MRD testing is appropriate. However, guidelines do not automatically replace national regulatory requirements.

Tools and Resources for MRD Laboratory Work

Reliable MRD analysis depends on more than the testing instrument. Laboratories also need validated procedures, trained personnel, quality checks, and suitable data-analysis methods.

Useful categories of tools and resources include:

• Flow cytometry analysis software: Helps evaluate cell populations and identify abnormal marker patterns.

• PCR data-analysis tools: Support the interpretation of amplification curves, target quantities, and assay controls.

• Sequencing analysis software: Helps identify genetic sequences, assess background errors, and quantify relevant molecular signals.

• Laboratory quality-management systems: Track sample identification, test procedures, calibration, and quality-control records.

• Bioinformatics pipelines: Process sequencing data and support consistent interpretation using validated analytical rules.

• Clinical interpretation templates: Organize findings, sample details, detection limits, and relevant limitations in laboratory reports.

• Scientific training materials: Explain assay validation, specimen preparation, molecular biology, and disease-specific testing guidance.

When comparing testing methods, laboratories should examine analytical sensitivity, specificity, reproducibility, sample requirements, turnaround time, and clinical validation. Results from different methods may not be directly interchangeable.

Frequently Asked Questions

What Does an MRD Test Detect?

An MRD test looks for small amounts of cancer-associated cells or molecular material that may remain after treatment. The specific target depends on the cancer and the method used.

What Is the Difference Between PCR and NGS for MRD Testing?

PCR focuses on selected genetic targets, while NGS examines many targeted sequences in parallel. Both can be highly sensitive when properly validated, but their suitability depends on the disease and clinical question.

Does a Negative MRD Result Mean Cancer Is Completely Gone?

No. A negative result means the test did not detect the targeted disease above its established detection limit in the sample examined. Cancer cells may still be present below that limit or outside the sampled material.

How Often Should MRD Testing Be Performed?

There is no single schedule for all cancers. Testing frequency depends on the disease, treatment stage, clinical guidelines, and the patient's circumstances. The treating clinician determines the appropriate monitoring plan.

Can MRD Testing Predict Cancer Recurrence?

MRD status can provide important information about recurrence risk in certain cancers. However, it cannot predict every outcome with certainty. Results must be interpreted with other clinical findings and the available evidence.

Conclusion

MRD testing technologies have expanded the ability to examine small amounts of residual cancer through flow cytometry, PCR, digital PCR, and next-generation sequencing. These methods can provide valuable information about treatment response and disease monitoring, particularly in selected blood cancers.